Mirikizumab Improves Quality of Life and Work Productivity in Patients with Moderately to Severely Active Crohn's Disease: Results from the Phase 3 VIVID-1 Study
Patients with moderately to severely active CD treated with mirikizumab reported clinically meaningful improvements in HRQoL and work productivity vs placebo at week 12, which were maintained at week 52.
Authors
- Kristina Traxler
- Frédérick Durand
- Severine A.R.A. Vermeire (ORCID: https://orcid.org/0000-0001-9942-3019)
- Ryan C. Ungaro (ORCID: https://orcid.org/0000-0001-8687-3758)
- Aisha Vadhariya (ORCID: https://orcid.org/0000-0002-1811-5370)
- Deborah A. Fisher (ORCID: https://orcid.org/0000-0002-8886-3382)
- Nathan Morris (ORCID: https://orcid.org/0000-0001-7989-5764)
- Millie D. Long (ORCID: https://orcid.org/0000-0001-5983-2758)
- Guanglei Yu (ORCID: https://orcid.org/0000-0003-0954-3397)
- Scott D. Lee (ORCID: https://orcid.org/0000-0001-8936-8052)
Institutions
- University of North Carolina at Chapel Hill (US)
- Eli Lilly (United States) (US)
- University of Washington Medical Center (US)
- Seattle University (US)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- The American Journal of Gastroenterology
- Published
- 2025-03-13
- DOI
- https://doi.org/10.14309/ajg.0000000000003410
- Citations
- 3
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 5.45